Latest news with #MesenchymalStemCells
Gulf Today
13-04-2025
- Health
- Gulf Today
Groundbreaking stem cell trial for knee osteoarthritis
The Department of Health - Abu Dhabi (DoH), has successfully completed a groundbreaking clinical trial in Abu Dhabi, in collaboration with Cellcolabs and Burjeel Holdings. Developed by Swedish biotech company Cellcolabs, StromaForte has shown a favourable safety profile and significant therapeutic potential for knee osteoarthritis, marking a significant step in evaluating cell-based therapies for degenerative joint diseases. The study evaluated the regenerative properties of Mesenchymal Stem Cells (MSCs), a type of stem cell known for its ability to reduce inflammation and repair and regenerate damaged tissues. Found naturally in the body, MSCs function as biological mediators by detecting areas of stress or injury and signalling the body to initiate its own healing process, rather than simply replacing damaged cells. In this clinical trial, patients received MSC injections derived from carefully screened healthy donors aged 18-30, directly into their affected knee joints. The goal was to confirm safety, ease pain, reduce inflammation and potentially repair cartilage damage, offering a potential alternative to surgery for those suffering from knee osteoarthritis. The clinical trial was led by Dr. Oussama Chaar, consultant Orthopaedic Surgeon and Dr. Veerabahu Muthusamy, specialist Orthopaedic Surgeon, and conducted at Burjeel Medical City and Burjeel Hospital from November 2023 to October 2024, where patients received a single dose of 50 million MSCs via ultrasound-guided injections. The results of the first phase (Phase I/II) of the trial have been encouraging, meeting its primary endpoint of safety confirmed by an independent safety monitoring board. Patients reported a significant reduction in pain levels, as measured by the Visual Analogue Scale (VAS), and an overall improvement in their quality of life, enabling them to move more comfortably and engage in daily activities with greater ease. Importantly, the treatment was well tolerated, with no serious adverse events reported. To further evaluate the therapy's efficacy, provide deeper insights into the therapy's impact, MRI scans have been conducted with detailed findings set to be presented at Abu Dhabi Global Health Week in April 2025. Dr. Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health - Abu Dhabi, highlighted, 'The successful completion of this clinical trial is a testament to Abu Dhabi's robust regulatory oversight and its growing appeal as a hub for cutting-edge medical research. WAM
Khaleej Times
12-04-2025
- Health
- Khaleej Times
Abu Dhabi successfully completes first groundbreaking stem cell trial for knee osteoarthritis
The Department of Health — Abu Dhabi (DoH), has successfully completed a groundbreaking clinical trial in Abu Dhabi, in collaboration with Cellcolabs and Burjeel Holdings. Developed by Swedish biotech company Cellcolabs, StromaForte has shown a favourable safety profile and significant therapeutic potential for knee osteoarthritis, marking a significant step in evaluating cell-based therapies for degenerative joint diseases. The study evaluated the regenerative properties of Mesenchymal Stem Cells (MSCs), a type of stem cell known for its ability to reduce inflammation and repair and regenerate damaged tissues. Found naturally in the body, MSCs function as biological mediators by detecting areas of stress or injury and signalling the body to initiate its own healing process, rather than simply replacing damaged cells. In this clinical trial, patients received MSC injections derived from carefully screened healthy donors aged 18-30, directly into their affected knee joints. The goal was to confirm safety, ease pain, reduce inflammation and potentially repair cartilage damage, offering a potential alternative to surgery for those suffering from knee osteoarthritis. The clinical trial was led by Dr. Oussama Chaar, consultant Orthopedic Surgeon and Dr. Veerabahu Muthusamy, specialist Orthopedic Surgeon, and conducted at Burjeel Medical City and Burjeel Hospital from November 2023 to October 2024, where patients received a single dose of 50 million MSCs via ultrasound-guided injections. The results of the first phase (Phase I/II) of the trial have been encouraging, meeting its primary endpoint of safety confirmed by an independent safety monitoring board. Patients reported a significant reduction in pain levels, as measured by the Visual Analogue Scale (VAS), and an overall improvement in their quality of life, enabling them to move more comfortably and engage in daily activities with greater ease. Importantly, the treatment was well tolerated, with no serious adverse events reported. To further evaluate the therapy's efficacy, provide deeper insights into the therapy's impact, MRI scans have been conducted with detailed findings set to be presented at Abu Dhabi Global Health Week in April 2025. 'The successful completion of this clinical trial is a testament to Abu Dhabi's robust regulatory oversight and its growing appeal as a hub for cutting-edge medical research. At the Department of Health – Abu Dhabi, we are committed to fostering a dynamic ecosystem that accelerates innovation while ensuring the highest standards of safety and ethics," Dr. Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health — Abu Dhabi, said. "By prioritising cell and gene therapies and regenerative medicine, we are paving the way for transformative treatments that improve patient outcomes and quality of life. These efforts reaffirm Abu Dhabi's position as a global leader in pioneering health innovations and shaping the future of precision medicine," she added. The clinical research was made possible through strong collaborations with global experts Cellcolabs, a member of Abu Dhabi's Hub71 global tech ecosystem, worked closely with DoH and Burjeel Medical City to bring this advanced stem cell treatment to patients in the UAE. Peter Ekstedt, CEO Cellcolabs UAE, commented, 'This clinical trial is a major milestone in Abu Dhabi's journey to becoming a global leader in regenerative medicine. At Cellcolabs, we are proud to contribute with our expertise in stem cells, to bring innovative, evidence-based solutions to patients suffering from knee osteoarthritis. By combining DOH's commitment to healthcare innovation with our advanced stem cell technology and know-how, we are paving the way for safer, more effective, and non-surgical treatments that can change the lives of thousands of patients suffering from OA in UAE.' Prof. Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, added, 'The success of the StromaForte trial is an exemplary showcase of Abu Dhabi's growing biotechnology sector. With continued research and development, stem cell therapy could transform osteoarthritis treatment, offering patients a non-surgical option for pain relief and improved mobility.'
Mid East Info
13-03-2025
- Health
- Mid East Info
Abu Dhabi Stem Cells Center and Yas Clinic first in UAE to receive AABB accreditation for haematopoietic progenitor cell collection
Abu Dhabi Stem Cells Center (ADSCC) and Yas Clinic have been granted a highly regarded global accreditation by AABB (formerly known as the American Association of Blood Banks) for Hematopoietic Progenitor Cell Collection. This achievement marks ADSCC and Yas Clinic as the first to earn this accreditation in the UAE, and the second in the Middle East and North Africa region (MENA), meeting the highest standards of quality and safety in in the procurement, processing, and storage of hematopoietic progenitor cells, which are critical for transplantation and treating various blood disorders and autoimmune diseases. As a Centre of Excellence in Hematopoietic Stem Cell Transplantation, accredited by the Department of Health Abu Dhabi and an accredited facility by the Foundation of Accreditation for Cellular Therapy (FACT), ADSCC and Yas Clinic's AABB accreditation further reinforces their commitment to excellence in cellular therapy and solidifies their leadership in regenerative medicine. Earning these three accreditations for cellular therapies in only 24 months is a testament to their dedication to the highest standards of quality, safety, and innovation in patient care within their Abu Dhabi Bone Marrow Transplant Program and their fully-fledged CAR-T and Mesenchymal Stem Cells programmes. Prof Yendry Ventura, Chief Executive Officer of ADSCC and Adjunct Professor at United Arab Emirates University, said: 'Under the visionary leadership of the UAE and in alignment with the national healthcare agenda, ADSCC and Yas Clinic remain dedicated to advancing cellular therapy and medical innovation on a global scale. Achieving AABB accreditation marks a significant milestone in our commitment to excellence in cellular therapies. As the first institution in the UAE to receive this prestigious accreditation, we continue to set new benchmarks in quality and patient safety which is backed by a solid infrastructure, a state-of-the-art apheresis and ECP unit, and unparalleled clinical expertise. This achievement underscores our dedication to pioneering cutting-edge treatments, enhancing healthcare standards, and reinforcing UAE's position as a regional leader in regenerative medicine and biological sciences.' Dr Maysoon Al Karam, Chief Medical Officer at Yas Clinic operated by ADSCC , said: 'This achievement reflects the efforts and expertise of our entire team of scientists, haematologists, immunologists, nurses and technicians and beyond. Being one of only two AABB-accredited facilities in the MENA region for HPC collection is a significant milestone for our patients and also physicians, and we are proud to contribute to the advancement of cellular therapy in the UAE and beyond. This accreditation positions ADSCC and Yas Clinic as a regional leader in bone marrow transplant and cellular therapy and reinforces our role in providing cutting-edge treatments to patients.' AABB's accreditation programme is the leader in ensuring the highest level of quality and safety for the blood and biotherapies field. AABB's accreditation programme promotes the highest standards of care for patients, donors, processes and products in all aspects of transfusion medicine, biotherapies and relationship testing. About Abu Dhabi Stem Cells Center ADSCC: Abu Dhabi Stem Cells Center (ADSCC) is a renowned healthcare institution in Abu Dhabi, UAE, specialising in advanced stem cell therapy, research, and regenerative medicine. ADSCC is the incubator of the Abu Dhabi Bone Marrow Transplant (AD-BMT © ) program, the first comprehensive programme to provide autologous and allogeneic hematopoietic stem cells transplant (HSCT) for adult and paediatric patients in the UAE since 2020. As a Center of Excellence in Hematopoietic Stem Cell Transplantation accredited by the Department of Health – Abu Dhabi, ADSCC's holistic service model includes advanced research, clinical trials, translational care, and manufacturing capabilities. ADSCC has one of the region's most advanced and sophisticated research labs and a robust multidisciplinary hospital. It is the only center in the UAE to encompass a cell processing laboratory, a state-of-the-art apheresis unit, a stem cell collection unit, a Good Manufacturing Practice (GMP) laboratory, and dedicated multi-specialty outpatient clinics and inpatient wards. As the UAE's first and most experienced stem cell transplant center, ADSCC has received multiple prestigious recognitions and conducted strategic collaborations, solidifying its position as a center of excellence. In 2024, ADSCC received accreditation from the Foundation for the Accreditation of Cellular Therapy (FACT) for its cellular therapy processing laboratory, the first in UAE and one of only two in Middle East to receive this global accreditation.
Associated Press
15-02-2025
- Health
- Associated Press
Breakthrough Study Highlights INDIBA Proionic 448kHz's Role in Stem Cell Proliferation.
SINGAPORE - Media OutReach Newswire - 15 February 2025 - A groundbreaking study has revealed that INDIBA Proionic 448kHz + 20kHz technology significantly promotes the proliferation of Mesenchymal Stem Cells (MSCs), unlocking new possibilities in beauty, wellness, and regenerative medicine. This research underscores the transformative potential of non-invasive radiofrequency treatments for improving everyday health and well-being, inspiring healthcare professionals and individuals interested in beauty and wellness technologies about its future applications. Revolutionizing Tissue Regeneration The study demonstrated that applying INDIBA's Proionic System at subthermal levels accelerates tissue regeneration through MSC proliferation. Mesenchymal Stem Cells, vital for tissue repair, showed a 38% increase in proliferation under controlled INDIBA treatment. This substantial increase in cell proliferation suggests a promising future for INDIBA technology in the field of regenerative medicine. This technology stimulates cells at a molecular level while preserving their ability to differentiate into cartilage, bone, and fat, offering a safe and natural approach to regenerative medicine. Transforming Everyday Beauty and Wellness This study offers possibilities for individuals seeking to enhance their beauty and wellness. MSCs' ability to rejuvenate skin, restore elasticity, and repair damaged tissues makes INDIBA an invaluable ally in the fight against signs of aging and skin imperfections. Moreover, this advancement greatly benefits sports rehabilitation by speeding up tissue repair and recovery. Key Findings The study conducted by Úbeda and colleagues demonstrated that intermittent exposure to a 448kHz electric stimulus applied through Capacitive-Resistive Electric Transfer (CRET) significantly promotes the proliferation of human mesenchymal stem cells. This finding is particularly relevant for treating various tissue injuries and degenerative conditions. Highlights of the Study: ● Cell Proliferation: MSCs exposed to 448kHz stimulation showed a 25% increase in cell count versus controls. ● Mechanism of Action: CRET effects stem from both direct cellular responses and not just thermal influence. ● Safety and Efficacy: Treatment preserved MSC multipotentiality, maintaining their differentiation capacity. The Science Behind INDIBA: Three Core Functions Biostimulation – Encourages cellular activity and regeneration without damaging cell integrity, enhancing tissue rejuvenation. Vascularization – Improves blood circulation, delivering essential nutrients and oxygen to tissues while removing toxins. Hyperactivation – Speeds up cellular metabolism, accelerating tissue repair and recovery. These functions work synergistically to create an environment where stem cells can thrive and contribute to tissue regeneration and wellness. Looking Ahead This study is a key step in understanding how radiofrequency energy enhances stem cell potential. With applications spanning beauty, wellness, and clinical rehabilitation, INDIBA continues to set the standard for innovation in non-invasive therapeutic technologies. Hashtag: #INDIBA The issuer is solely responsible for the content of this announcement. About INDIBA INDIBA is a global leader in radiofrequency technology. With over 40 years of experience developing non-invasive solutions that enhance beauty, wellness, and clinical recovery, INDIBA is based in Barcelona, Spain. It continues to pioneer innovative treatments that empower individuals worldwide. INDIBA Asia Headquarters is based in Singapore.
Zawya
15-02-2025
- Health
- Zawya
Breakthrough Study Highlights INDIBA Proionic 448kHz's Role in Stem Cell Proliferation.
SINGAPORE - Media OutReach Newswire - 15 February 2025 - A groundbreaking study has revealed that INDIBA Proionic 448kHz + 20kHz technology significantly promotes the proliferation of Mesenchymal Stem Cells (MSCs), unlocking new possibilities in beauty, wellness, and regenerative medicine. This research underscores the transformative potential of non-invasive radiofrequency treatments for improving everyday health and well-being, inspiring healthcare professionals and individuals interested in beauty and wellness technologies about its future applications. Revolutionizing Tissue Regeneration The study demonstrated that applying INDIBA's Proionic System at subthermal levels accelerates tissue regeneration through MSC proliferation. Mesenchymal Stem Cells, vital for tissue repair, showed a 38% increase in proliferation under controlled INDIBA treatment. This substantial increase in cell proliferation suggests a promising future for INDIBA technology in the field of regenerative medicine. This technology stimulates cells at a molecular level while preserving their ability to differentiate into cartilage, bone, and fat, offering a safe and natural approach to regenerative medicine. Transforming Everyday Beauty and Wellness This study offers possibilities for individuals seeking to enhance their beauty and wellness. MSCs' ability to rejuvenate skin, restore elasticity, and repair damaged tissues makes INDIBA an invaluable ally in the fight against signs of aging and skin imperfections. Moreover, this advancement greatly benefits sports rehabilitation by speeding up tissue repair and recovery. Key Findings The study conducted by Úbeda and colleagues demonstrated that intermittent exposure to a 448kHz electric stimulus applied through Capacitive-Resistive Electric Transfer (CRET) significantly promotes the proliferation of human mesenchymal stem cells. This finding is particularly relevant for treating various tissue injuries and degenerative conditions. Highlights of the Study: ● Cell Proliferation: MSCs exposed to 448kHz stimulation showed a 25% increase in cell count versus controls. ● Mechanism of Action: CRET effects stem from both direct cellular responses and not just thermal influence. ● Safety and Efficacy: Treatment preserved MSC multipotentiality, maintaining their differentiation capacity. The Science Behind INDIBA: Three Core Functions Biostimulation – Encourages cellular activity and regeneration without damaging cell integrity, enhancing tissue rejuvenation. Vascularization – Improves blood circulation, delivering essential nutrients and oxygen to tissues while removing toxins. Hyperactivation – Speeds up cellular metabolism, accelerating tissue repair and recovery. These functions work synergistically to create an environment where stem cells can thrive and contribute to tissue regeneration and wellness. Looking Ahead This study is a key step in understanding how radiofrequency energy enhances stem cell potential. With applications spanning beauty, wellness, and clinical rehabilitation, INDIBA continues to set the standard for innovation in non-invasive therapeutic technologies. For more details, read the original study in Cell Physiology and Biochemistry, a reputable scientific journal : Hashtag: #INDIBA The issuer is solely responsible for the content of this announcement. About INDIBA INDIBA is a global leader in radiofrequency technology. With over 40 years of experience developing non-invasive solutions that enhance beauty, wellness, and clinical recovery, INDIBA is based in Barcelona, Spain. It continues to pioneer innovative treatments that empower individuals worldwide. INDIBA Asia Headquarters is based in Singapore. For more information, contact: +65 6292 0100, or visit INDIBA
